Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 14550 participants.

Also called NCT06008756

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 14,550 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06008756
  • jRCT jRCT2071230064
  • EU CT 2022-502781-24-00
  • WHO UTN U1111-1285-4245
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06008756. Randomized; triple masking; primary purpose treatment. Start 2023-10-09 (actual); primary completion 2029-11-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Condition
Arteriosclerosis
Condition
Hypercholesterolaemia
Intervention (Drug)
Enlicitide Decanoate
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct06008756
Content hash
1cbe42b43ecd0a3cf28deefe7a7eb17ef9b7fd4249562567c88876c324d4727d